Physiological effects of caffeine, epigallocatechin-3-gallate, and exercise in overweight and obese women.
The aim of this study was to evaluate the combined effects of a 10-week exercise program with ingestion of caffeine and epigallocatechin-3-gallate (EGCG) on body composition, cardiovascular fitness, and strength in overweight and obese women. In a double-blind, placebo-controlled approach, overweight and obese women (n = 27) were randomly assigned to treatment groups with exercise (an active-supplementing group with exercise (EX-Act) and a placebo group with exercise (EX-PL)) or without exercise (an active-supplementing group without exercise (NEX-Act) and a placebo group without exercise (NEX-PL)). All participants consumed 1 drink per day for 10 weeks; EX-Act and EX-PL participated in a concurrent endurance and resistance training program. Changes in body composition were assessed using a 4-compartment model. Changes in muscle mass (MM) were evaluated using a DXA-derived appendicular lean-soft tissue equation. There was a significant time × treatment interaction for MM (p = 0.026) and total cholesterol (TC) (p = 0.047), and a significant time × training interaction for peak oxygen consumption (p = 0.046) and upper-body and lower-body strength (p < 0.05). Significant differences between the EX groups and NEX groups for percentage change in MM and peak oxygen consumption, and upper-body and lower-body strength, were revealed. Clinical markers for hepatic and renal function revealed no adverse effects. TC significantly decreased for the active-supplementing groups (EX-Act, NEX-Act). The current study suggests that implementing a caffeine-EGCG-containing drink prior to exercise may improve MM, fitness, and lipid profiles in overweight women.
Smith
Abbie E
AE
Department of Health and Exercise Science, University of Oklahoma, 1401 Asp Avenue, Norman, OK 73019, USA.
Lockwood
Christopher M
CM
Moon
Jordan R
JR
Kendall
Kristina L
KL
Fukuda
David H
DH
Tobkin
Sarah E
SE
Cramer
Joel T
JT
Stout
Jeffrey R
JR
D000293:Adolescent; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage; D001823:Body Composition / Q000187:drug effects; D002110:Caffeine / Q000008:administration & dosage*; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003131:Combined Modality Therapy; D015444:Exercise / Q000502:physiology*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage; D010807:Physical Endurance / Q000187:drug effects*; D010809:Physical Fitness / Q000502:physiology; D055815:Young Adult
D000975:Antioxidants; D008055:Lipids; D010726:Phosphodiesterase Inhibitors; D002110:Caffeine; D002392:Catechin; C045651:epigallocatechin gallate